Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Bristol-Myers Squibb Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (61)
Cancellation by sponsor (42)
Prescription medicine registration (35)
Australian Public Assessment Report (AusPAR) (33)
Designation or determination (5)
Prescription medicine decision summary (2)
Prescription medicine evaluation (2)
Section 14, TGO91 consent (2)

Date

2026 (6)
2025 (13)
2024 (6)
2023 (6)
2022 (18)
2021 (9)
2020 (15)
2019 (4)
2018 (23)
2017 (18)
2016 (5)
2015 (14)
2014 (4)
2013 (7)
2012 (5)
2011 (10)
2010 (3)
2009 (3)
2007 (12)
2004 (1)

Search

Sponsor content

182 result(s) found, displaying 51 to 60

DAKLINZA daclatasvir (as dihydrochloride) 30 mg tablet blister Cancelled under Section 30(1)(c) of the Act

7 March 2022

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
DAKLINZA daclatasvir (as dihydrochloride) 60 mg tablet blister Cancelled under Section 30(1)(c) of the Act

7 March 2022

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)

31 January 2022

Prescription medicine registration

Active ingredients: nivolumab.
OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)

31 January 2022

Prescription medicine registration

Active ingredients: nivolumab.
OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)

22 November 2021

Prescription medicine registration

Active ingredients: nivolumab.
REYATAZ atazanavir 150mg capsule bottle Cancelled under Section 30(1)(c) of the Act

4 October 2021

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)

30 September 2021

Prescription medicine registration

Active ingredients: nivolumab.
AusPAR: Nivolumab and ipilimumab

11 May 2021

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Nivolumab and ipilimumab
WINGLORE, YERVOY (Bristol-Myers Squibb Australia Pty Ltd)

7 May 2021

Prescription medicine registration

Active ingredients: ipilimumab.
OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)

7 May 2021

Prescription medicine registration

Active ingredients: nivolumab.

Pages

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Page 10
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.